Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study

Diabetes, Obesity and Metabolism

Volumn 18, Issue 6, 2016, Pages 598-606

  Davis, T M E ^a   Chubb, S A P ^a,b,c,d   Bruce, D G ^a   Davis, W A ^a  

^a FREMANTLE HOSPITAL   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d FIONA STANLEY HOSPITAL   (Australia)

Author keywords

glycaemic control; observational study; type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; COMMUNITY LIVING; DIET THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; VALIDATION STUDY; VASCULAR DISEASE; CAUSE OF DEATH; GLUCOSE BLOOD LEVEL; INDEPENDENT LIVING; LONG TERM CARE; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

AGED; BLOOD GLUCOSE; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDEPENDENT LIVING; LONG-TERM CARE; MALE; MIDDLE AGED;

EID: 84963669785     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12655     Document Type: Article

References (32)

1. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413–420.
2. Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 2012; 7: e42551.
3. Eeg-Olofsson K, Cederholm J, Nilsson PM et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010; 268: 471–482.
4. Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011; 34: 77–83.
5. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481–489.
6. Monami M, Vitale V, Lamanna C et al. HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for personalised therapeutic targets. Nutr Metab Cardiovasc Dis 2013; 23: 300–306.
7. Hemmingsen B, Lund SS, Gluud C et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 11: CD008143.
8. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001; 111: 633–642.
9. Kahler P, Grevstad B, Almdal T et al. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open 2014; 4: e004806.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.
12. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.
13. Advance Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.
14. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011.
15. Davis TM, Bruce DG, Davis WA. Cohort profile: the Fremantle Diabetes Study. Int J Epidemiol 2013; 42: 412–421.
16. Davis TM, Hunt K, McAullay D et al. Continuing disparities in cardiovascular risk factors and complications between aboriginal and Anglo-Celt Australians with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2012; 35: 2005–2011.
17. Norman PE, Davis WA, Bruce DG, Davis TM. Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2006; 29: 575–580.
18. Holman CD, Bass AJ, Rosman DL et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev 2008; 32: 766–777.
19. Jones BL, Nagin DS. A note on a Stata plugin for estimating group-based trajectory models. Sociol Methods Res 2013; 42: 608–613.
20. Jones BL, Nagin DJ, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res 2001; 29: 374–393.
21. Berlin KS, Parra GR, Williams NA. An introduction to latent variable mixture modeling (part 2): longitudinal latent class growth analysis and growth mixture models. J Pediatr Psychol 2014; 39: 188–203.
22. Smagula SF, Butters MA, Anderson SJ et al. Antidepressant response trajectories and associated clinical prognostic factors among older adults. JAMA Psychiatry 2015; 72: 1021–1028.
23. Chang HY, Wahlqvist ML, Liu WL et al. Management trajectories in the type 2 diabetes Integrated Delivery System project in Taiwan: accounting for behavioral therapy, nutrition education and therapeutics. Asia Pac J Clin Nutr 2014; 23: 592–606.
24. Walraven I, Mast MR, Hoekstra T et al. Distinct HbA1c trajectories in a type 2 diabetes cohort. Acta Diabetol 2015; 52: 267–275.
25. Thiebaut AC, Benichou J. Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study. Stat Med 2004; 23: 3803–3820.
26. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
28. Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and vascular metabolic memory: truth or fiction? Curr Diab Rep 2013; 13: 403–410.
29. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604–612.
30. Sanon VP, Sanon S, Kanakia R et al. Hypoglycemia from a cardiologist's perspective. Clin Cardiol 2014; 37: 499–504.
31. Sillars B, Davis WA, Hirsch IB, Davis TM. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 2010; 12: 757–765.
32. Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410–1418.